Glenmark Generics Inc., a subsidiary of Glenmark Pharmaceuticals, has received US FDA approval for lamotrigine 25, 100, 150 and 200 mg tablets, the generic version of Lamictal by GlaxoSmithKline. Lamotrigine is an anti-epileptic drug indicated for epilepsy and bipolar disorder.

According to IMS Health sales data for the 12 months period ending December 2011, the annual sales of lamotrigine tablets touched to US$ 62 million.

Glenmark's current portfolio consists of 80 products authorized for distribution in the US marketplace and 38 ANDAs pending approval with the US FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.